Dr. Laura Hall -- Pharmaceutical Payment Report

This page provides a comprehensive transparency report for Dr. Laura Hall, a Pulmonology physician based in City, VA. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Laura Hall has received $45,168.33 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.

Physician Profile

The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.

Payment Summary

Dr. Laura Hall has received a total of $45,168.33 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $45,168.33 per transaction.

Payment Breakdown by Category

The following table shows how Dr. Laura Hall's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.

Payment CategoryAmountDescription
Speaking & Education$45,168.33Promotional speaking, CME events, and educational presentations

The largest payment category for Dr. Laura Hall is Speaking & Education, accounting for 100% ($45,168.33) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.

Pharmaceutical Company Relationships

The following pharmaceutical and medical device companies have made payments to Dr. Laura Hall. Click on any company name to view their full physician payment profile and spending patterns.

CompanyTotal PaidTransactions
Roche/Genentech$45,168.331

Dr. Laura Hall has a financial relationship with Roche/Genentech, receiving $45,168.33 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.

Drugs and Medical Devices Referenced in Payments

The following drugs and medical devices have been referenced in pharmaceutical payments to Dr. Laura Hall. These references indicate that the payment was related to the marketing, consulting, or clinical use of these products.

The presence of a drug or device in a payment record means the pharmaceutical company associated the payment with that product. This is common for consulting fees related to a specific medication, speaking engagements about a product, or research involving a particular drug or device.

AI Transparency Analysis

The following analysis was generated by artificial intelligence based on Dr. Laura Hall's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.

Laura Hall has received $45.2K across 1 pharmaceutical payments as a Pulmonology physician in City, VA. Top paying companies include Roche/Genentech ($45.2K). Dr. Hall received a single, substantial payment of $45,168 in 2024. This payment was exclusively from Roche/Genentech and was for speaking engagement. The payment is associated with the drug Tecfidera.

Patient Guidance: Questions to Ask Your Doctor

If Dr. Laura Hall is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:

Patients may wish to inquire about any potential influence on treatment decisions given the singular, significant payment received by Dr. Hall. Always feel free to ask your doctor directly about their pharmaceutical relationships.

Peer Comparison: How Dr. Laura Hall Compares to Other Pulmonology Physicians

As a Pulmonologist, Dr. Hall's payment profile is unique due to the single, high-value speaking engagement reported.

Recent Payment Records

The following table shows the most recent pharmaceutical industry payments recorded for Dr. Laura Hall in the CMS Open Payments database. Click on any payment to view the full report.

CompanyAmountTypeDrug/DeviceDateConflict Level
Roche/Genentech$45,168.33speakingTecfidera2024-04-26Not Assessed

Frequently Asked Questions About Dr. Laura Hall's Pharma Payments

Below are common questions patients ask about physician pharmaceutical payment data.

How much pharma money has Laura Hall received?

Laura Hall has received a total of $45.2K across 1 payments from pharmaceutical companies. This data is publicly reported under the CMS Open Payments (Sunshine Act) program.

Is Laura Hall taking too much pharma money?

Laura Hall has received $45.2K in pharmaceutical payments. Whether this is "too much" depends on the physician's specialty (Pulmonology), the types of payments, and how they compare to peers. The largest payment category is speaking ($45.2K). Payment does not imply wrongdoing, but patients should be aware and can ask their doctor directly.

What pharma companies pay Laura Hall?

The top pharmaceutical companies paying Laura Hall are: Roche/Genentech ($45.2K). These payments cover various categories including consulting, meals, speaking fees, and research grants.

What kinds of payments does Laura Hall receive?

Laura Hall's payments by type: speaking: $45.2K.

Should I switch doctors because of pharma payments?

Pharma payments alone are not typically reason to switch doctors. Many payments are routine (like meals at educational events) and do not indicate compromised care. Focus on: (1) whether your doctor explains treatment options clearly, (2) whether generic alternatives are discussed, (3) the overall pattern of payments, not individual transactions. If you have concerns, ask your doctor directly.

How do Laura Hall's payments compare to other Pulmonology doctors?

To compare, look at the total amount ($45.2K), number of payments (1), and the types of payments received. Pulmonology physicians may receive different payment amounts depending on subspecialty, geographic location, and academic affiliation. Use CMS Open Payments data to compare across the specialty.

How can I verify Laura Hall's payment data?

You can verify this data directly through the CMS Open Payments database at openpaymentsdata.cms.gov. Search by physician name or NPI number (1022309690). All data is reported by pharmaceutical companies and verified by CMS. DoctorPharmaData aggregates this public data for easier access.

Do pharma payments affect prescribing quality?

Research published in JAMA Internal Medicine and other peer-reviewed journals shows a statistical association between pharmaceutical payments and prescribing patterns. However, correlation does not equal causation. Many physician-industry interactions are legitimate (research, education, advisory boards). The Sunshine Act was created to promote transparency so patients can make informed decisions.

What stands out about Laura Hall's pharma payment profile?

The doctor's payment profile is highly concentrated with 100% of payments coming from a single company. Laura Hall has received $45.2K in total pharma payments.

How does Laura Hall compare to peers in Pulmonology?

As a Pulmonologist, Dr. Hall's payment profile is unique due to the single, high-value speaking engagement reported.

Are Laura Hall's pharma relationships typical for Pulmonology?

The entire payment history consists of one transaction, making trend analysis difficult.

What should patients of Laura Hall know about these payments?

Patients may wish to inquire about any potential influence on treatment decisions given the singular, significant payment received by Dr. Hall.

What patterns are visible in Laura Hall's payment history?

The payment type is specifically categorized as 'speaking'.

Understanding This Doctor Payment Report

This transparency report for Dr. Laura Hall is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:

About the Physician Payments Sunshine Act

The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.

Under this law, Dr. Laura Hall's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.

The Open Payments data for Dr. Laura Hall and all other physicians can be accessed at the official CMS Open Payments website.

Related Resources

Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.